Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 54 | 3,984 | 40% |
| 2020 | 54 | 3,619 | 43% |
| 2021 | 58 | 3,927 | 48% |
| 2022 | 56 | 3,580 | 52% |
| 2023 | 54 | 3,704 | 56% |
| 2024 | 52 | 3,646 | 59% |
| 2025 from claims | – | 3,600 3,304–3,809 | 61% |
| 2026 forecast | – | 3,684 3,241–4,251 | 62% |
| 2027 forecast | – | 3,754 3,209–4,474 | 62% |
| 2028 forecast | – | 3,823 3,190–4,681 | 63% |
| 2029 forecast | – | 3,891 3,178–4,880 | 64% |
| 2030 forecast | – | 3,958 3,171–5,072 | 65% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 53% of the cases CMS names in North Carolina; 23 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 43% inpatient hospital, 53% hospital outpatient, 5% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 119 | 8,114−0.6%/yr | −0.6%/yr | 3.7 | 6% | 9,910 in 2030+3.4%/yr |
| Texas | 130 | 7,585−0.2%/yr | −0.2%/yr | 3.6 | 6% | 10,200 in 2030+5.1%/yr |
| Virginia | 48 | 3,175+1.2%/yr | +1.2%/yr | 3.1 | 0% | 3,690 in 2030+2.6%/yr |
| Maryland | 36 | 2,499+2.9%/yr | +2.9%/yr | 2.9 | 1% | 3,770 in 2030+7.1%/yr |
| South Carolina | 38 | 2,414+3.9%/yr | +3.9%/yr | 3.6 | 1% | 3,510 in 2030+6.4%/yr |
| Tennessee | 45 | 1,981−2.7%/yr | −2.7%/yr | 2.9 | 7% | 2,310 in 2030+2.6%/yr |
| Georgia | 39 | 1,940−4.2%/yr | −4.2%/yr | 2.3 | 0% | 2,330 in 2030+3.1%/yr |
| Kentucky | 24 | 1,609−3%/yr | −3%/yr | 3.6 | 2% | 1,660 in 2030+0.5%/yr |
| Louisiana | 24 | 1,549−3.9%/yr | −3.9%/yr | 3.9 | 11% | 1,580 in 2030+0.3%/yr |
| Alabama | 21 | 1,343−4.1%/yr | −4.1%/yr | 3.1 | 11% | 1,700 in 2030+4%/yr |
| West Virginia | 12 | 913−4.3%/yr | −4.3%/yr | 4.5 | 0% | 1,000 in 2030+1.5%/yr |
| Oklahoma | 13 | 913−5.4%/yr | −5.4%/yr | 1.9 | 0% | 1,080 in 2030+2.9%/yr |
| Arkansas | 12 | 721−1.7%/yr | −1.7%/yr | 1.9 | 0% | 990 in 2030+5.4%/yr |
| District of Columbia | 6 | 706−0.3%/yr | −0.3%/yr | 11.4 | 0% | 760 in 2030+1.2%/yr |
| Mississippi | 11 | 634−4%/yr | −4%/yr | 1.7 | 5% | 710 in 2030+1.9%/yr |
| Delaware | 10 | 417−1.5%/yr | −1.5%/yr | 2.5 | 0% | 470 in 2030+2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 544 | 112,191−5.4%/yr | −5.4%/yr | 117.81.0× | 61% | 111,000 in 2030−0.2%/yr |
| Bronchoscopy & lung nodule | 56 | 3,414+0.2%/yr | +0.2%/yr | 3.51.0× | 0% | 4,080 in 2030+3%/yr |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Capsovision leads with 56% of company spending on these surgeons in 2025, +52 pts on 2024.
In 2025, 15 companies reported engagement with North Carolina’s surgeons worth $176K in consulting, speaking, meals and travel tied to these products, about $3,385 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 43264 (ercp remove duct calculi), commercial plans pay North Carolina’s hospitals a median of $3,803, from $3,803 at the lowest to $4,683 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.